Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 3,685 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-small Cell Lung Cancers Clear all
Terminated Early Phase 1 Interventional

Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer

NCT01525446
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
SBRT with proton beam radiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 31, 2026, 11:30 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer

NCT00179686
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
CC-5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Metairie, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2006 · Synced Oct 31, 2026, 11:30 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

NCT05118854
View directory record Official record
Conditions
Lung Cancer
Interventions
AMG 510, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 31, 2026, 11:30 PM EDT
Completed Phase 1 Interventional

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

NCT02840994
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
CV301, Pembrolizumab, Nivolumab
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Tampa, Florida • Indianapolis, Indiana • Metairie, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 31, 2026, 11:30 PM EDT
Completed Phase 2 Interventional

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

NCT00112346
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Cetuximab + platinum + gemcitabine, Platinum + Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
31
States / cities
Mobile, Alabama • Anchorage, Alaska • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 31, 2026, 11:30 PM EDT
Terminated Phase 3 Interventional Results available

Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer

NCT00113386
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, pegfilgrastim, cisplatin, docetaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
76
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Concord, California + 64 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2013 · Synced Oct 31, 2026, 11:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

NCT02487095
View directory record Official record
Conditions
Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma, Uterine Cervical Neoplasms, Carcinoma, Neuroendocrine, Extrapulmonary Small Cell Cancer
Interventions
Topotecan, VX-970 (M6620)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 31, 2026, 11:30 PM EDT
Not listed Phase 1 Interventional

PBF-1129 in Patients With NSCLC

NCT03274479
View directory record Official record
Conditions
Locally Advanced or Metastatic NSCLC
Interventions
PBF-1129
Drug
Lead sponsor
Palobiofarma SL
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 31, 2026, 11:30 PM EDT
Completed Not applicable Interventional Results available

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

NCT02728596
View directory record Official record
Conditions
Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer, Stage I Colorectal Cancer, Stage IA Breast Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Breast Cancer, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIC Colorectal Cancer, Stage IIIA Breast Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IIIC Colorectal Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
3,665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
159
States / cities
Jonesboro, Arkansas • Martinez, California • Augusta, Georgia + 134 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 31, 2026, 11:30 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

NCT01877083
View directory record Official record
Conditions
KIF5B-RET-Positive Adenocarcinoma of the Lung
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Whittier, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 31, 2026, 11:30 PM EDT
Completed Not applicable Interventional

Thoracoscopy in Patients With Stage IIIA Non-Small Cell Lung Cancer

NCT00003566
View directory record Official record
Conditions
Lung Cancer
Interventions
videothoracoscopy
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
71
States / cities
Anniston, Alabama • La Jolla, California • San Diego, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 31, 2026, 11:30 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy

NCT00998166
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Pemetrexed, Cisplatin, Bevacizumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Lake Success, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 31, 2026, 11:30 PM EDT
Terminated Phase 2 Interventional Results available

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

NCT03871153
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer
Interventions
Durvalumab, Paclitaxel, Carboplatin, Radiation, Surgical Resection
Device · Drug · Radiation + 1 more
Lead sponsor
Greg Durm, MD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 31, 2026, 11:30 PM EDT
Suspended Phase 1Phase 2 Interventional

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

NCT05642195
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
Interventions
Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803, Ventana PD-L1 (SP263 or SP142) assay
Biological · Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 11:30 PM EDT
Completed Phase 2 Interventional Results available

A Study of SEA-CD40 Given With Other Drugs in Cancers

NCT04993677
View directory record Official record
Conditions
Melanoma, Carcinoma, Non-Small- Cell Lung
Interventions
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, carboplatin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
23
States / cities
Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 31, 2026, 11:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

NCT06303505
View directory record Official record
Conditions
Ovarian Cancer, Non-small Cell Lung Cancer
Interventions
TUB-040
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • New Haven, Connecticut • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 31, 2026, 11:30 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

NCT02109653
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
LGX818
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 31, 2026, 11:30 PM EDT
Terminated Phase 2 Interventional

Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

NCT02642939
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Mifepristone
Drug
Lead sponsor
Check, Jerome H., M.D., Ph.D.
Individual
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Melrose Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 31, 2026, 11:30 PM EDT
Completed Phase 2 Interventional Results available

Bupropion in Helping Adults Stop Smoking

NCT00534001
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
bupropion hydrochloride, placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 31, 2026, 11:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

NCT07355205
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions
Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 31, 2026, 11:30 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

NCT02422381
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
MK-3475, Gemcitabine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 31, 2026, 11:30 PM EDT
Completed Phase 2 Interventional Results available

Regimen for the Treatment of Cachexia in Subjects With NSCLC

NCT00527319
View directory record Official record
Conditions
Cachexia
Interventions
VT-122 low dose, VT-122 high dose
Drug
Lead sponsor
Vicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 31, 2026, 11:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

NCT07538804
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ANS02
Drug
Lead sponsor
Avistone Biotechnology Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 31, 2026, 11:30 PM EDT
Active, not recruiting Phase 2 Interventional

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 11:30 PM EDT